A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

Inclusion Criteria: * Male or female, 18-55 years of age, inclusive * Able to provide written informed consent * BMI between 19.0 and 35.0 kg/m2, inclusive * 12-lead ECG at Screening and pre-dose with no clinically significant abnormalities * Highly effective, double barrier contraception (both male and female partners) during the study and for 3 months following the dose of ARC-520 * Willing and able to comply with all study assessments * Suitable venous access for blood sampling * Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and creatinine levels in the normal range * No abnormal finding of clinical relevance Exclusion Criteria: * Pregnant/lactating * Acute signs of hepatitis/other infection within 4 weeks of Screening * Concurrent use of anticoagulants, corticosteroids, immunomodulators, or immunosuppressants. * Use of prescription medication within 14 days prior to study treatment * Depot injection/implant other than birth control within 3 months of study treatment * Known diagnosis of diabetes mellitus * History of autoimmune disease especially autoimmune hepatitis. * Human immunodeficiency virus (HIV) infection * Sero-positive for hepatitis B virus (HBV) or hepatitis C virus (HCV) * Uncontrolled hypertension: blood pressure (BP) \> 150/100 mmHg * History of cardiac rhythm disturbances * Family history of congenital long QT syndrome, Brugada syndrome or unexplained sudden cardiac death. * Currently uses medications known to prolong the corrected QT interval (QTc). * Symptomatic heart failure (per New York Heart Association guidelines) * Unstable angina, myocardial infarction, severe cardiovascular disease, transient ischemic attack (TIA) or cerebrovascular accident (CVA) within past 6 months * History of malignancy within last 5 years except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer * Major surgery within 3 months of Screening * History of alcohol and/or drug abuse \< 12 months from Screening * Regular use of alcohol within 6 months of Screening * Evidence of systemic acute inflammation, sepsis or hemolysis. * Clinically significant psychiatric disorder * Use of recreational drugs within 3 months of Screening or drugs, such as cocaine, phencyclidine (PCP), and methamphetamines, within 1 year of Screening * Positive urine drug screen * History of allergy or hypersensitivity reaction to bee venom * Positive reaction to the bee venom immunoglobulin E \[IgE\] test * Use of investigational agents or devices within 30 days of study dosing or current participation in an investigational study. * Clinically significant history/presence of any gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease * Cholangitis, cholecystitis, cholestasis, or duct obstruction * Clinically significant history/presence of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, metabolic or other uncontrolled systemic disease * Blood donation or blood loss (500 mL) within 30 days prior to study treatment * History of fever within 2 weeks of Screening. * Excessive exercise/physical activity within 7 days of Screening or enrollment or planned during the study. * History of coagulopathy, stroke within six (6) months of baseline, and/or concurrent anticoagulant medication(s)